Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6523MR)

This product GTTS-WQ6523MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6523MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6375MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ15117MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ6921MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9011MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ5092MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ6076MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13124MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ4743MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW